Drugs / VE303
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04236778 | Nov 2017 → Mar 2019 | — | Vedanta Biosciences, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04899115 | Aug 2021 → Apr 2023 | cirrhosis of liver, hepatic encephalopathy | Patricia Bloom | Completed | No outcome recorded |
| Phase 2 | NCT03788434 | Feb 2019 → Jun 2021 | CADINS disease, Clostridium difficile colitis | Vedanta Biosciences, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06237452 | May 2024 → Jun 2027 expected | CADINS disease, Clostridium difficile colitis, intestinal infectious disease | Vedanta Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VE303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237452 ↗ |
| Modality | Other / unclassified | “VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.” NCT03788434 ↗ |
| Route | Oral | “orally once daily for 14 days.” PMID 37060545 ↗ Apr 2023 |